CymaBay Therapeutics (NASDAQ:CBAY) Lifted to “Strong-Buy” at ValuEngine

ValuEngine upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from a buy rating to a strong-buy rating in a research note released on Thursday, ValuEngine reports.

Several other analysts have also weighed in on the company. BidaskClub lowered CymaBay Therapeutics from a sell rating to a strong sell rating in a report on Tuesday, July 30th. Stifel Nicolaus assumed coverage on CymaBay Therapeutics in a report on Monday, June 24th. They set a buy rating and a $14.00 price target on the stock. B. Riley set a $7.00 price target on CymaBay Therapeutics and gave the company a hold rating in a report on Monday, June 17th. Cantor Fitzgerald set a $20.00 price target on CymaBay Therapeutics and gave the company a buy rating in a report on Sunday, April 14th. Finally, Oppenheimer set a $12.00 price target on CymaBay Therapeutics and gave the company a buy rating in a report on Tuesday, June 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. CymaBay Therapeutics presently has an average rating of Buy and an average target price of $14.00.

NASDAQ:CBAY traded down $0.08 during midday trading on Thursday, hitting $6.06. 478,532 shares of the company traded hands, compared to its average volume of 674,934. The firm has a fifty day moving average price of $6.65. CymaBay Therapeutics has a 12-month low of $4.82 and a 12-month high of $14.00. The stock has a market cap of $421.78 million, a price-to-earnings ratio of -4.81 and a beta of 1.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.66 and a quick ratio of 18.66.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). On average, analysts anticipate that CymaBay Therapeutics will post -1.49 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in CBAY. Swiss National Bank boosted its position in shares of CymaBay Therapeutics by 2.1% during the 2nd quarter. Swiss National Bank now owns 112,900 shares of the biopharmaceutical company’s stock worth $808,000 after acquiring an additional 2,300 shares in the last quarter. Aperio Group LLC acquired a new position in shares of CymaBay Therapeutics during the 2nd quarter worth about $104,000. Bailard Inc. boosted its position in shares of CymaBay Therapeutics by 43.5% during the 2nd quarter. Bailard Inc. now owns 308,700 shares of the biopharmaceutical company’s stock worth $2,210,000 after acquiring an additional 93,600 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of CymaBay Therapeutics in the 2nd quarter valued at about $252,000. Finally, Sphera Funds Management LTD. acquired a new stake in shares of CymaBay Therapeutics in the 1st quarter valued at about $4,589,000. Institutional investors and hedge funds own 98.74% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Further Reading: Gap Down Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.